Device
TheraBionic P1
TheraBionic P1 is a medical device with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
2
50%
Ph not_applicable
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (50.0%)
N/A2 (50.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingnot_applicable
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
NCT07118202
not_yet_recruitingnot_applicable
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
NCT07227831
recruitingphase_2
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
NCT07130903
recruitingphase_2
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
NCT06576115
Clinical Trials (4)
Showing 4 of 4 trials
NCT07118202Not Applicable
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
NCT07227831Not Applicable
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
NCT07130903Phase 2
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
NCT06576115Phase 2
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 4